Anti-FGFR1/KLB monoclonal antibody - GLP1R agonist peptide (Sanofi)

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameAnti-FGFR1/KLB monoclonal antibody - GLP1R agonist peptide (Sanofi)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-FGFR1Anti-Klotho betaGlucagon-like peptide 1 receptor agonists

TargetsFibroblast growth factor receptor 1Klotho betaGlucagon-like peptide 1 receptor

Therapy Area/IndicationsDiabetes Mellitus

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSanofi

China Registration ClassN/A

Develop Information

Active CompaniesSanofi

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus

Inactive IndicationsN/A

Other Information

ATC CodeN/A